Sihuan Pharmaceutical Holdings Group (HK:0460) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sihuan Pharmaceutical Holdings Group Ltd. has announced that their subsidiary, Huisheng Biopharmaceutical, received drug registration approval from China’s National Medical Products Administration for their new Calcium Dobesilate Capsules, intended to treat microvascular diseases linked to diabetes. This development is significant considering the high prevalence of diabetes in China, with a substantial number of patients suffering from related microvascular diseases. The company, known for its comprehensive diabetes care solutions, continues to expand its product portfolio in the domain of diabetes treatment and complications.
For further insights into HK:0460 stock, check out TipRanks’ Stock Analysis page.
